Dexmedetomidine inhibits tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide-stimulated astrocytes by suppression of c-Jun N-terminal kinases

Inflammation

Volumn 37, Issue 3, 2014, Pages 942-949

  Zhang, Xiaobao ^a   Wang, Jun ^a   Qian, Wenyi ^a   Zhao, Jingjing ^a   Sun, Li ^a   Qian, Yanning ^a   Xiao, Hang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

astrocyte; cytokine; dexmedetomidine; inflammation; JNK

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DEXMEDETOMIDINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IMMUNOREGULATION; INFLAMMATION; NERVE CELL STIMULATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTHRACENES; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; CELL SURVIVAL; CELLS, CULTURED; DEXMEDETOMIDINE; GENE EXPRESSION; INFLAMMATION; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902543621     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9814-4     Document Type: Article

References (48)

1. Eng, L.F., and R.S. Ghirnikar. 1994. GFAP and astrogliosis. Brain Pathology 4: 229-237. (Pubitemid 24261929)
2. Aschner, M. 1998. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 19: 269-281.
3. Aschner, M., U. Sonnewald, and K.H. Tan. 2002. Astrocyte modulation of neurotoxic injury. Brain Pathology 12: 475-481. (Pubitemid 35154935)
4. Munoz-Fernandez, M.A., and M. Fresno. 1998. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Progress in Neurobiology 56: 307-340. (Pubitemid 28389722)
5. Barcia, C., C.M. Ros, V. Annese, A. Gomez, F. Ros-Bernal, D. Aguado-Llera, M.E. Martinez-Pagan, V. de Pablos, E. Fernandez-Villalba, and M.T. Herrero. 2012. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Disease 3: e379.
6. Sato, S., O. Takeuchi, T. Fujita, H. Tomizawa, K. Takeda, and S. Akira. 2002. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and - independent pathways. International Immunology 14: 783-791. (Pubitemid 34814639)
7. Choi, Y., M.K. Lee, S.Y. Lim, S.H. Sung, and Y.C. Kim. 2009. Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. British Journal of Pharmacology 156: 933-940.
8. Pocivavsek, A., M.P. Burns, and G.W. Rebeck. 2009. Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57: 444-453.
9. Gorina, R., T. Santalucia, V. Petegnief, A. Ejarque-Ortiz, J. Saura, and A.M. Planas. 2009. Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA. Glia 57: 93-107.
10. Zhang, X., J. Feng, P. Zhu, and Z. Zhao. 2013. Ketamine inhibits calcium elevation and hydroxyl radical and nitric oxide production in lipopolysaccharide-stimulated NR8383 alveolar macrophages. Inflammation 36: 1094-1100.
11. Bhana, N., K.L. Goa, and K.J. McClellan. 2000. Dexmedetomidine. Drugs 59: 263-268. discussion 269-270.
12. Candiotti, K.A., S.D. Bergese, P.M. Bokesch, M.A. Feldman, W. Wisemandle, and A.Y. Bekker. 2010. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesthesia and Analgesia 110: 47-56.
13. Cooper, L., K. Candiotti, C. Gallagher, E. Grenier, K.L. Arheart, and M.E. Barron. 2011. A randomized, controlled trial on dexmedetomidine for providing adequate sedation and hemodynamic control for awake, diagnostic transesophageal echocardiography. Journal of Cardiothoracic and Vascular Anesthesia 25: 233-237.
14. Gu, J., J. Chen, P. Xia, G. Tao, H. Zhao, and D. Ma. 2011. Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice. Acta Anaesthesiologica Scandinavica 55: 1272-1278.
15. Polat, B., Y. Albayrak, B. Suleyman, H. Dursun, F. Odabasoglu, M. Yigiter, Z. Halici, and H. Suleyman. 2011. Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats. Pharmacological Reports 63: 518-526.
16. Yang, C.L., C.H. Chen, P.S. Tsai, T.Y. Wang, and C.J. Huang. 2011. Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. The Journal of Surgical Research 167: e273-e281.
17. Peng, M., Y.L. Wang, C.Y. Wang, and C. Chen. 2012. Dexmedetomidine attenuates lipopolysaccharide-induced proinflammatory response in primary microglia. The Journal of Surgical Research 179: e219-e225.
18. Bell, M.T., F. Puskas, D.T. Bennett, P.S. Herson, N. Quillinan, D.A. Fullerton, and T.B. Reece. 2013. Dexmedetomidine, an alpha-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion. Journal of Thoracic and Cardiovascular Surgery. doi:10.1016/j.jtcvs.2013.07.043.
19. Sato, K., T. Kimura, T. Nishikawa, Y. Tobe, and Y. Masaki. 2010. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. Acta Anaesthesiologica Scandinavica 54: 377-382.
20. Ebersolt, C., M. Perez, and J. Bockaert. 1981. Alpha 1 and alpha 2 Adrenergic receptors in mouse brain astrocytes from primary cultures. Journal of Neuroscience Research 6: 643-652. (Pubitemid 12206342)
21. Enkvist, M.O., H. Hamalainen, C.C. Jansson, J.P. Kukkonen, R. Hautala, M.J. Courtney, and K.E. Akerman. 1996. Coupling of astroglial alpha 2-adrenoreceptors to second messenger pathways. Journal of Neurochemistry 66: 2394-2401. (Pubitemid 26159074)
22. Panickar, K.S., and M.D. Norenberg. 2005. Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 50: 287-298. (Pubitemid 40780835)
23. Rao, K.V., K.S. Panickar, A.R. Jayakumar, and M.D. Norenberg. 2005. Astrocytes protect neurons from ammonia toxicity. Neurochemical Research 30: 1311-1318. (Pubitemid 41772278)
24. Giaume, C., A. Koulakoff, L. Roux, D. Holcman, and N. Rouach. 2010. Astroglial networks: a step further in neuroglial and gliovascular interactions. Nature Review Neuroscience 11: 87-99.
25. Giaume, C. 2010. Astroglial wiring is adding complexity to neuroglial networking. Frontiers in Neuroenergetics . doi:10.3389/fnene.2010.00129.
26. Gleichman, A.J., and S.T. Carmichael. 2013. Astrocytic therapies for neuronal repair in stroke. Neuroscience Letters . doi:10.1016/j.neulet.2013.10. 055.
27. Engelhard, K., C. Werner, E. Eberspacher, M. Bachl, M. Blobner, E. Hildt, P. Hutzler, and E. Kochs. 2003. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesthesia and Analgesia 96: 524-531. (Pubitemid 36125776)
28. Chen, Z., T.B. Gibson, F. Robinson, L. Silvestro, G. Pearson, B. Xu, A. Wright, C. Vanderbilt, and M.H. Cobb. 2001. MAP kinases. Chemistry Review 101: 2449-2476. (Pubitemid 35373029)
29. Kozuka, N., Y. Kudo, and M. Morita. 2007. Multiple inhibitory pathways for lipopolysaccharide- and pro-inflammatory cytokine-induced nitric oxide production in cultured astrocytes. Neuroscience 144: 911-919. (Pubitemid 46013997)
30. Iirola, T., R. Laitio, E. Kentala, R. Aantaa, J.P. Kurvinen, M. Scheinin, and K.T. Olkkola. 2010. Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report. Journal of Medical Case Reports 4: 73.
31. Hayashi, Y., K. Sumikawa, M. Maze, A. Yamatodani, T. Kamibayashi, M. Kuro, and I. Yoshiya. 1991. Dexmedetomidine prevents epinephrine-induced arrhythmias through stimulation of central alpha 2 adrenoceptors in halothane-anesthetized dogs. Anesthesiology 75: 113-117.
32. Benggon, M., H. Chen, R. Applegate, R. Martin, and J.H. Zhang. 2012. Effect of dexmedetomidine on brain edema and neurological outcomes in surgical brain injury in rats. Anesthesia and Analgesia 115: 154-159.
33. Ebert, T.J., J.E. Hall, J.A. Barney, T.D. Uhrich, and M.D. Colinco. 2000. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 93: 382-394. (Pubitemid 30620311)
34. Lai, Y.C., P.S. Tsai, and C.J. Huang. 2009. Effects of dexmedetomidine on regulating endotoxin-induced up-regulation of inflammatory molecules in murine macrophages. The Journal of Surgical Research 154: 212-219.
35. Engelhard, K., C. Werner, S. Kaspar, O. Mollenberg, M. Blobner, M. Bachl, and E. Kochs. 2002. Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 96: 450-457. (Pubitemid 34121758)
36. Taniguchi, T., Y. Kidani, H. Kanakura, Y. Takemoto, and K. Yamamoto. 2004. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Critical Care Medicine 32: 1322-1326. (Pubitemid 38738587)
37. Bekker, A., and M.K. Sturaitis. 2005. Dexmedetomidine for neurological surgery. Neurosurgery 57: 1-10.
38. Zhang, Y., and H.K. Kimelberg. 2005. Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia. Current Neuropharmacology 3: 317-323. (Pubitemid 41461248)
39. Kuhmonen, J., J. Pokorny, R. Miettinen, A. Haapalinna, J. Jolkkonen, P. Riekkinen Sr., and J. Sivenius. 1997. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 87: 371-377. (Pubitemid 27435380)
40. Maier, C., G.K. Steinberg, G.H. Sun, G.T. Zhi, and M. Maze. 1993. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 79: 306-312. (Pubitemid 23224843)
41. Yan, M., H. Dai, T. Ding, A. Dai, F. Zhang, L. Yu, G. Chen, and Z. Chen. 2011. Effects of dexmedetomidine on the release of glial cell line-derived neurotrophic factor from rat astrocyte cells. Neurochemistry International 58: 549-557.
42. Xu, B., W.S. Zhang, J.L. Yang, N. Lu, X.M. Deng, H. Xu, and Y.Q. Zhang. 2010. Evidence for suppression of spinal glial activation by dexmedetomidine in a rat model of monoarthritis. Clinical and Experimental Pharmacology & Physiology 37: e158-e166.
43. Lenormand, P., G. Pages, C. Sardet, G. L'Allemain, S. Meloche, and J. Pouyssegur. 1993. MAP kinases: activation, subcellular localization and role in the control of cell proliferation. Advances in Second Messenger and Phosphoprotein Research 28: 237-244.
44. Chen, Y.R., W. Wang, A.N. Kong, and T.H. Tan. 1998. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. The Journal of Biological Chemistry 273: 1769-1775. (Pubitemid 28133709)
45. Swantek, J.L., M.H. Cobb, and T.D. Geppert. 1997. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Molecular and Cellular Biology 17: 6274-6282. (Pubitemid 27451171)
46. Shen, J., I. Sakaida, K. Uchida, S. Terai, and K. Okita. 2005. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sciences 77: 1502-1515. (Pubitemid 40961994)
47. Chow, J.C., D.W. Young, D.T. Golenbock, W.J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. The Journal of Biological Chemistry 274: 10689-10692.
48. Lien, E., T.K. Means, H. Heine, A. Yoshimura, S. Kusumoto, K. Fukase, M.J. Fenton, M. Oikawa, N. Qureshi, B. Monks, R.W. Finberg, R.R. Ingalls, and D.T. Golenbock. 2000. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. Journal of Clinical Investigation 105: 497-504. (Pubitemid 30127250)